AVBP (ArriVent BioPharma) Research & Development: $129.68 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVBP ArriVent BioPharma Inc AVBP
12 GF Score
Price $32.54
! 2 Warning Signs
View Full Analysis

What is ArriVent BioPharma Research & Development?

ArriVent BioPharma AVBP -3.27% 12 Research & Development is $129.68 Mil as of Mar. 2026. GuruFocus rates AVBP with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ArriVent BioPharma's Research & Development for the three months ended in Mar. 2026 was $37.62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $129.68 Mil.

ArriVent BioPharma  (NAS:AVBP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ArriVent BioPharma Research & Development Related Terms

ArriVent BioPharma Research & Development Historical Data

* Premium members only.

The historical data trend for ArriVent BioPharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma Research & Development Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 30.43 64.88 79.00 153.35

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.29 27.72 32.17 32.18 37.62
AVBP
12GF Score
ArriVent BioPharma Inc AVBP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ArriVent BioPharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $129.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $129.68 Mil mean?
ArriVent BioPharma (AVBP) has a Research & Development of $129.68 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ArriVent BioPharma and its competitors.
Is ArriVent BioPharma's Research & Development too high?
ArriVent BioPharma's current Research & Development is $129.68 Mil. Overall, ArriVent BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does ArriVent BioPharma's Research & Development compare to MAZE and DMRA?
ArriVent BioPharma's Research & Development of $129.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ArriVent BioPharma and its competitors. ArriVent BioPharma's current Research & Development is $129.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArriVent BioPharma stock overvalued right now?
ArriVent BioPharma (AVBP) has a current Research & Development of $129.68 Mil. The current Research & Development is $129.68 Mil. ArriVent BioPharma's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ArriVent BioPharma (AVBP), the current Research & Development is $129.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ArriVent BioPharma Business Description

Address 18 Campus Boulevard, Suite 100, Newtown Square, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
12GF Score

Get the complete analysis for AVBP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.54
Price